Search research articles
Contact Us
Filters
Showing results (201-210 of 274) with videos related to
Page
of 28
Sort By:
American Journal of Hematology
|
January 22, 2024
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma
Xuehan Mao, Wenqiang Yan, David Mery, et al.
Cancer Biomarkers : Section a of Disease Markers
|
June 9, 2025
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
Fumou Sun, Yan Cheng, Catherine Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 11, 2013
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease
Razelle Kurzrock, Peter M Voorhees, Corey Casper, et al.
Stem Cells (Dayton, Ohio)
|
July 7, 2011
Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone
Xin Li, Wen Ling, Angela Pennisi, et al.
American Journal of Hematology
|
March 14, 2022
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma
Meera Mohan, Sravani Gundarlapalli, Aniko Szabo, et al.
British Journal of Haematology
|
July 10, 2021
High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse
Eileen M Boyle, Adam Rosenthal, Yan Wang, et al.
Haematologica
|
March 24, 2018
Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma
Faith E Davies, Adam Rosenthal, Leo Rasche, et al.
American Journal of Hematology
|
April 7, 2017
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
Meera Mohan, Amy Buros, Pankaj Mathur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 5, 2016
Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
James E McDonald, Marcus M Kessler, Michael W Gardner, et al.
Bone Marrow Transplantation
|
December 22, 2022
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
Samer Al Hadidi, Aniko Szabo, Jean Esselmann, et al.
Page
of 28
Search research articles
Search
Showing results (201-210 of 274) with videos related to
Sort By:
Page
of 28
American Journal of Hematology
|
January 22, 2024
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma
Xuehan Mao, Wenqiang Yan, David Mery, et al.
Cancer Biomarkers : Section a of Disease Markers
|
June 9, 2025
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
Fumou Sun, Yan Cheng, Catherine Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 11, 2013
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease
Razelle Kurzrock, Peter M Voorhees, Corey Casper, et al.
Stem Cells (Dayton, Ohio)
|
July 7, 2011
Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone
Xin Li, Wen Ling, Angela Pennisi, et al.
American Journal of Hematology
|
March 14, 2022
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma
Meera Mohan, Sravani Gundarlapalli, Aniko Szabo, et al.
British Journal of Haematology
|
July 10, 2021
High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse
Eileen M Boyle, Adam Rosenthal, Yan Wang, et al.
Haematologica
|
March 24, 2018
Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma
Faith E Davies, Adam Rosenthal, Leo Rasche, et al.
American Journal of Hematology
|
April 7, 2017
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
Meera Mohan, Amy Buros, Pankaj Mathur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 5, 2016
Assessment of Total Lesion Glycolysis by <sup>18</sup>F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
James E McDonald, Marcus M Kessler, Michael W Gardner, et al.
Bone Marrow Transplantation
|
December 22, 2022
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
Samer Al Hadidi, Aniko Szabo, Jean Esselmann, et al.
Page
of 28